Unknown

Dataset Information

0

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma.

ABSTRACT: A 20-year-old woman was diagnosed with stage 4 lung adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 20 insertion gene mutation. Although the patient underwent chemotherapy, her lesions progressed. Liquid biopsy for EGFR T790M mutation showed negative results. After administering osimertinib, reduction of the lesions at the primary site was observed, and the patient's respiratory condition improved. Previous reports showing successful treatment of EGFR exon 20 insertion-positive lung adenocarcinoma with the standard osimertinib dose of 80 mg are limited. The present case demonstrated that osimertinib could be a possible treatment option for EGFR exon 20 insertion-positive lung adenocarcinoma.

SUBMITTER: Murano C 

PROVIDER: S-EPMC6806250 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma.

Murano Chihiro C   Igarashi Akira A   Yamauchi Keiko K   Inoue Sumito S   Watanabe Masafumi M  

EXCLI journal 20191007

A 20-year-old woman was diagnosed with stage 4 lung adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 20 insertion gene mutation. Although the patient underwent chemotherapy, her lesions progressed. Liquid biopsy for EGFR T790M mutation showed negative results. After administering osimertinib, reduction of the lesions at the primary site was observed, and the patient's respiratory condition improved. Previous reports showing successful treatment of EGFR exon 20 insertion-positi  ...[more]

Similar Datasets

Unknown Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report.
| S-EPMC7572000 | biostudies-literature
Unknown EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
| S-EPMC6580637 | biostudies-literature
Unknown Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel <i>EGFR</i> Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases.
| S-EPMC8573166 | biostudies-literature
Unknown A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
| S-EPMC8080261 | biostudies-literature
Unknown EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
| S-EPMC3714231 | biostudies-literature
Unknown Targeting <i>EGFR</i> exon 20 insertion mutations in non-small cell lung cancer.
| S-EPMC6405763 | biostudies-literature
Unknown HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib.
| S-EPMC7411254 | biostudies-literature
Unknown [Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].
| S-EPMC7049789 | biostudies-literature
Unknown EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma.
| S-EPMC8774177 | biostudies-literature
Unknown Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
| S-EPMC9262839 | biostudies-literature